SBP GROUP (01177.HK): Preclinical Data of Oral STAT6 Degrader TQH5528 Presented at ERS 2026

NewTimeSpace News: On 8 September 2026, Sino Biopharmaceutical Limited (stock code: 01177) issued a voluntary announcement stating that preclinical study data of TQH5528, an oral STAT6 degrader independently developed by its subsidiary Chia Tai-Tianqing Pharmaceutical Group Co., Ltd., had been presented as an oral presentation at the European Respiratory Society International Congress 2026 (ERS 2026), together with an accompanying e-poster.

According to the announcement, TQH5528 is an oral STAT6 degrader developed on a proprietary oral protein degrader technology platform (OAPD) with global intellectual property rights. It targets the IL-4/IL-13/STAT6 signalling axis and exerts efficacy through a protein degradation mechanism, with potential to become a next-generation therapy that is more convenient to administer than injectable biologics. The molecule features a novel CRBN ligand structure with no IMiD-related activity, picomolar-level potent STAT6 degradation activity, superior inhibition of the IL-4/IL-13 pathway versus comparator molecule KT-621, and good oral exposure and bioavailability across multiple species.

Preclinical data showed that in in vitro cell assays, TQH5528 demonstrated stronger activity than KT-621 and dupilumab in degrading STAT6 protein, inhibiting pSTAT6 and suppressing downstream inflammatory cytokine release. In non-human primate studies, a single dose achieved significant STAT6 downregulation, daily multiple dosing achieved complete STAT6 degradation in blood within four hours, and low doses achieved more than 95% STAT6 degradation in tissues such as the spleen, lung and peripheral blood mononuclear cells. In an HDM-induced IL-4/IL-4R humanised asthma mouse model, the product significantly improved airway hyperresponsiveness, reduced peripheral inflammatory cells and improved eosinophil infiltration; in vivo safety studies are ongoing.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.